Store
CAR-T Cell Therapy Market Review
Publication Date: December 19, 2019
Tags: Biopharma, CAR-T Cell Therapy, Immunoassay, Life Science, Oncology and Cancer, Pharma & Biopharma
Pages: 59
SKU: 19-099
CAR-T Cell Therapy Market Review provides an insightful examination of CAR-T therapy, a revolutionary form of immunotherapy harnessing the body’s T cells to target and eradicate cancer cells. This report delves into the technology behind CAR-T, its application in treating diseases like acute lymphoblastic leukemia, DLBCL B-cell lymphomas, and multiple myeloma.
Key Objectives and Questions Answered:
- Analysis of CAR-T market revenue growth and its sustainability
- Projections on market expansion and potential limitations
- Insights into global cancer burden and emerging market trends
Evaluation of major players and competition landscape
For further details and to purchase directly, please contact us.
Table of Contents
1: Executive Summary
Introduction
CAR-T Therapy Market Trends, Issues, and Recent Developments
CAR-T Therapy Market
Companies in the Market
2: CAR-T Cell Therapy Market
FDA-Approved CAR-T Therapies: Yescarta and Kymriah
- Yescarta
- Kymriah
- Table 2-1: FDA-Approved CAR-T Therapies
CAR-T Therapy Market Trends / Issues
- Global Cancer Burden
- Figure 2-1: Global Cancer Incidence Trends, 2010-2040
- Complexity of the CARs Manufacturing Process
- Diseases Treated with CAR-T
Recent Market Developments
- Study Shows Yescarta Increases Longevity
- CRS and Other Side Effects
- China CAR-T Competition
- Indian CAR-T Competition
- “Off-the-Shelf” CAR-T Therapies in Development
- A Competing Therapy in Development
Selected CAR-T Therapies in Development
-
- Table 2-2: Selected CAR-T Therapies in Development
- KTE-X19
- liso-cel
- C-CAR088
- IBI326 (Innovent) / CT103A (IASO BIO)
- bb21217
- MB-107
- ICTCAR014
- bb2121
- JNJ-682284528 (JNJ-4528)
- CT053
- MB-101 (IL-13Ra2)
- MB-108 (oncolytic virus C134)
- CYAD-01
- BAFF-R CAR-T
- MB-105 (PSCA)
- MB-102 (CD123)
- MB-103 (HER2)
- P-BCMA-101
- LCAR-B38M
- JCARH125
- MCARH171
- CYAD-101
- MB-106 (CD20)
- MB-104 (CS1)
- AMG 119
- ATA2271
- AUTO1
- AUTO3
CAR-T Market Analysis
-
- Figure 2-2: CAR-T Market, 2018-2024 ($millions)
- Market Share
- Figure 2-3: CAR-T Market Share, 2019 (%)
- Regional Breakout
- Figure 2-4: CAR-T Market Regional Breakout, 2019 (%)
3: Companies in the Market
AbbVie, Inc.
- Company Summary
- Scripps Research Institute Deal
- Tyrosine Kinase Inhibitors Market
Autolus Therapeutics plc
Bellicum Pharmaceuticals, Inc.
bluebird bio, Inc.
- Company Summary
- bb2121
- bb21217
- bb2121
Bristol-Myers Squibb Company
- Company Summary
- BMS Acquires Celgene
- Monoclonal Antibodies Market
- Cancer Kinase Inhibitor Market
CARsgen Therapeutics
Celgene Corporation
- Company Summary
- Collaboration with Immatics Biotechnologies
- Celgene Acquires Juno, Developer of CAR-T and TCR Therapeutics, for $9 Billion
- Celgene Buys JAK2 Inhibitor Maker
Cellectis, Inc.
- Pfizer
- Servier
Celyad
- CYAD-01
- CYAD-101
Gilead Sciences, Inc.
GlaxoSmithKline
Gracell Biotechnology
Immune Therapeutics
- CAR-T
Innovative Cellular Therapeutics
- ICTCAR014
Juno Therapeutics
- Selected CAR-T Therapies in Development
- Collaboration with Editas Medicine
Kite Pharma, Inc.
- KTE-X19
- Yescarta
Mustang Bio
Novartis International AG
- Company Summary
- Kymriah
- Intellia Therapeutics
- Other Company Activity
Pfizer, Inc.
Sorrento Therapeutics
ZIOPHARM Oncology, Inc.
Related products
In Vitro Diagnostic (IVD) Procedure Volumes, 2023-2028
October 22, 2023
Gain invaluable insights into the global IVD market with Kalorama Information’s comprehensive report In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028. This analysis provides essential data on the number of IVD procedures, offering a gold standard for new entrants and existing marketers in the diagnostic products industry.
…
$6,000.00 – $9,000.00
The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition
March 7, 2024
Explore the cutting-edge world of molecular point-of-care (mPOC) diagnostic solutions with our latest report, offering a detailed analysis of the market and future growth potential from 2023-2028. mPOC technology revolutionizes diagnostic capabilities, providing enhanced sensitivity and specificity compared to traditional near-patient tests. These solutions are instrumental in critical care units, physician offices, outpatient clinics,…
$5,000.00 – $7,875.00
In Vitro Diagnostics Business Outlook, 2024
December 20, 2024
In Vitro Diagnostics Business Outlook, 2024 is a must-have publication offering exclusive information and data that cannot be found elsewhere. With a focus on the in vitro diagnostics (IVD) market, this publication provides valuable insights to help businesses identify growth opportunities, understand market trends, and tailor strategies for success.
Key Features:
…
$4,995.00 – $9,995.00
